Azathioprine for long-term maintenance of remission in autoimmune hepatitis

New England Journal of Medicine

Volumn 333, Issue 15, 1995, Pages 958-963

  Johnson, Philip J ^a   Mcfarlane, Ian G ^a   Williams, Roger ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE AMINOTRANSFERASE; AUTOANTIBODY; AZATHIOPRINE; GLOBULIN; HLA ANTIGEN; LIVER ENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; ARTICLE; AUTOIMMUNE HEPATITIS; BONE MARROW SUPPRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUSHINGOID SYNDROME; DOSE RESPONSE; DRUG MIXTURE; FEMALE; HUMAN; LIVER BIOPSY; LIVER FAILURE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALAISE; MALE; MALIGNANT TRANSFORMATION; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; RASH; REMISSION; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ARTHRALGIA; AUTOIMMUNE DISEASES; AZATHIOPRINE; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PLATELET COUNT; PREDNISOLONE; RECURRENCE; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 0029130857     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199510123331502     Document Type: Article

References (33)

1. The Copenhagen Study Group for Liver Diseases. Effect of prednisone on the survival of patients with cirrhosis of the liver. Lancet 1969; 1: 119-121
2. Cook GC, Mulligan R, Sherlock S Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971; 40: 159-185
3. Soloway RD, Summerskill WHJ, Baggenstoss AH, Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972; 63: 820-833
4. Murray-Lyon IM, Stern RB, Williams R Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973; 1: 735-737
5. Hegarty JE, Nouri Aria KT, Portmann B, Eddleston ALWF, Williams R Relapse following treatment withdrawal in patients with autoimmune chronic active hepatitis. Hepatology 1983; 3: 685-689
6. Czaja AJ, Beaver SJ, Shiels MT Sustained remission after corticosteroid therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Gastroenterology 1987; 92: 215-219
7. Czaja AJ. Treatment of autoimmune hepatitis. In: Nishioka M, Toda G, Zeniya M, eds. Autoimmune hepatitis. Amsterdam: Elsevier, 1994:283-304.
8. Stellon AJ, Hegarty JE, Portmann B, Williams R Randomised controlled trial of azathioprine withdrawal in autoimmune chronic active hepatitis. Lancet 1985; 1: 668-670
9. Stellon AJ, Keating JJ, Johnson PJ, McFarlane IG, Williams R Maintenance of remission in autoimmune chronic active hepatitis with azathioprine after corticosteroid withdrawal. Hepatology 1988; 8: 781-784
10. Johnson PJ, McFarlane IG Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993; 18: 998-1005
11. McFarlane BM, McSorley CG, Vergani D, McFarlane IG, Williams R Serum autoantibodies reacting with the hepatic asialoglycoprotein receptor protein (hepatic lectin) in acute and chronic liver disorders. J Hepatol 1986; 3: 196-205
12. Donaldson PT, Doherty DG, Hayllar KM, McFarlane IG, Johnson PJ, Williams R Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1-B8-DR3 are independent risk factors. Hepatology 1991; 13: 701-706
13. Doherty DG, Vaughan RW, Donaldson PT, Mowat AP HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids. Hum Immunol 1992; 34: 53-63
14. Diem K, Seldrup J. Introduction to statistics, statistical tables, mathematical formulae. In: Lentner C, ed. Geigy scientific tables. Vol. 2. Basel, Switzerland: Ciba– Geigy, 1982.
15. Naber AH, Van Haelst U, Yap SH Nodular regenerative hyperplasia of the liver: an important cause of portal hypertension in non-cirrhotic patients. J Hepatol 1991; 12: 94-99
16. Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20: 88-94
17. Van Scoik KG, Johnson CA, Porter WR The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab Rev 1985; 16: 157-174
18. Schmiegelow K, Kriegbaum NJ 6-Thioguanine nucleotide accumulation in erythrocytes during azathioprine treatment for systemic connective tissue diseases: a possible index for monitoring treatment. Ann Rheum Dis 1993; 52: 152-154
19. Weinshilboum RM, Sladek SL Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651-662
20. Lennard L, Van Loon JA, Weinshilboum RM Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989; 46: 149-154
21. Lennard L, Lilleyman JS, Van Loon J, Weinshilboum RM Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet 1990; 336: 225-229
22. Golbus MS Teratology for the obstetrician: current status. Obstet Gynecol 1980; 55: 269-277
23. Witter FR, King TM. Drugs and the management of chronic diseases in the pregnant patient. In: Stern L, ed. Drug use in pregnancy. Balgowlah, Australia: ADIS Health Science Press, 1984:190-211.
24. Wang KK, Czaja AJ, Beaver SJ, Go VL Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. Hepatology 1989; 10: 39-43
25. Silman AJ, Petrie J, Hazleman B, Evans SJ Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study. Ann Rheum Dis 1988; 47: 988-992
26. Viteri A, Vernace SJ, Schaffner F Extrahepatic malignancy in chronic liver disease: report of six cases. Gastroenterology 1976; 71: 1075-1078
27. Kinlen LJ Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985; 78: 44-49
28. McFarlane IG, Eddleston ALWF. Chronic active hepatitis. In: Targan SR, Shanahan F, eds. Immunology and immunopathology of the liver and gastrointestinal tract. New York: Igaku-Shoin, 1990:281-304.
29. Nouri-Aria KT, Hegarty JE, Alexander GJM, Eddleston ALWF, Williams R Effect of corticosteroids on suppressor-cell activity in “autoimmune” and viral chronic active hepatitis. N Engl J Med 1982; 307: 1301-1304
30. Pedersen BK, Beyer JM, Rasmussen A, Azathioprine as single drug in the treatment of rheumatoid arthritis induces complete suppression of natural killer cell activity. Acta Pathol Microbiol Immunol Scand [C] 1984; 92: 221-225
31. Prince HE, Ettenger RB, Dorey FJ, Fine RN, Fahey JL Azathioprine suppression of natural killer activity and antibody-dependent cellular cytotoxicity in renal transplant recipients. J Clin Immunol 1984; 4: 312-318
32. Nouri-Aria KT, Hegarty JE, Alexander GJM, Eddleston ALWF, Williams R IgG production in “autoimmune” chronic active hepatitis: effect of prednisolone on T and B lymphocyte function. Clin Exp Immunol 1985; 61: 290-296
33. Pedersen BK, Beyer JM A longitudinal study of the influence of azathioprine on natural killer cell activity. Allergy 1986; 41: 286-289